Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dominika Écsiová

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Ceskoslovenska Patologie|April 17, 2026
Castleman disease - one name, many facesKateřina Kamarádová, Václav Stejskal, Dominika Écsiová
Cancers|July 2, 2021
Chemoimmunotherapy in the First-Line Treatment of Chronic Lymphocytic Leukaemia: Dead Yet, or Alive and Kicking?Lukáš Smolej, Pavel Vodárek, Dominika Écsiová, et al.
Acta Medica (Hradec Kralove)|March 24, 2026
Are We Moving Toward Curative Approaches in Chronic Lymphocytic Leukemia?Martin Šimkovič, Eva Vejražková, Dominika Écsiová, et al.
Journal of Pharmaceutical and Biomedical Analysis|July 13, 2022
High-throughput salting-out assisted liquid-liquid extraction using a 3D printed device and its application in the quantification of ibrutinib and its metabolite PCI-45227 in human serumDominika Écsiová, Martin Šimkovič, Martin Uher, et al.
Cancer Medicine|November 28, 2022
A comprehensive assessment of lymphocyte subsets, their prognostic significance, and changes after first-line therapy administration in patients with chronic lymphocytic leukemiaPavel Vodárek, Dominika Écsiová, Vladimíra Řezáčová, et al.
Cancer Medicine|August 9, 2024
Complex evaluation of serum immunoglobulin levels in patients with chronic lymphocytic leukemia: Significant increase in IgA after first-line chemoimmunotherapyPavel Vodárek, Dominika Écsiová, Vladimíra Řezáčová, et al.
European Journal of Clinical Investigation|October 6, 2020
Rituximab, Cyclophosphamide and Dexamethasone (RCD) Chemoimmunotherapy for Relapsed Chronic Lymphocytic LeukaemiaMartin Šimkovič, Pavel Vodárek, Monika Motyčková, et al.
British Journal of Haematology|March 27, 2023
Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR)Martin Špaček, Lukáš Smolej, Martin Šimkovič, et al.
Annals of Hematology|February 27, 2023
COVID-19 in patients with chronic lymphocytic leukemia: a multicenter analysis by the Czech CLL study groupMartin Šimkovič, Peter Turcsányi, Martin Špaček, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Ceskoslovenska Patologie|April 17, 2026
Castleman disease - one name, many facesKateřina Kamarádová, Václav Stejskal, Dominika Écsiová
Cancers|July 2, 2021
Chemoimmunotherapy in the First-Line Treatment of Chronic Lymphocytic Leukaemia: Dead Yet, or Alive and Kicking?Lukáš Smolej, Pavel Vodárek, Dominika Écsiová, et al.
Acta Medica (Hradec Kralove)|March 24, 2026
Are We Moving Toward Curative Approaches in Chronic Lymphocytic Leukemia?Martin Šimkovič, Eva Vejražková, Dominika Écsiová, et al.
Journal of Pharmaceutical and Biomedical Analysis|July 13, 2022
High-throughput salting-out assisted liquid-liquid extraction using a 3D printed device and its application in the quantification of ibrutinib and its metabolite PCI-45227 in human serumDominika Écsiová, Martin Šimkovič, Martin Uher, et al.
Cancer Medicine|November 28, 2022
A comprehensive assessment of lymphocyte subsets, their prognostic significance, and changes after first-line therapy administration in patients with chronic lymphocytic leukemiaPavel Vodárek, Dominika Écsiová, Vladimíra Řezáčová, et al.
Cancer Medicine|August 9, 2024
Complex evaluation of serum immunoglobulin levels in patients with chronic lymphocytic leukemia: Significant increase in IgA after first-line chemoimmunotherapyPavel Vodárek, Dominika Écsiová, Vladimíra Řezáčová, et al.
European Journal of Clinical Investigation|October 6, 2020
Rituximab, Cyclophosphamide and Dexamethasone (RCD) Chemoimmunotherapy for Relapsed Chronic Lymphocytic LeukaemiaMartin Šimkovič, Pavel Vodárek, Monika Motyčková, et al.
British Journal of Haematology|March 27, 2023
Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR)Martin Špaček, Lukáš Smolej, Martin Šimkovič, et al.
Annals of Hematology|February 27, 2023
COVID-19 in patients with chronic lymphocytic leukemia: a multicenter analysis by the Czech CLL study groupMartin Šimkovič, Peter Turcsányi, Martin Špaček, et al.
Pageof 1